How does the ketogenic diet induce anti-seizure effects?

Neuroscience Letters

Volumn 637, Issue , 2017, Pages 4-10

  Rho, Jong M ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Epilepsy; Ketogenic diet; Mechanism; Metabolism; Mitochondria; Oxidative stress

Indexed keywords

DEOXYGLUCOSE; DOCOSAHEXAENOIC ACID; FATTY ACID; ICOSAPENTAENOIC ACID; ION CHANNEL; KETONE BODY; LINOLEIC ACID; NEUROTRANSMITTER; OMEGA 3 FATTY ACID; PLACEBO; POLYUNSATURATED FATTY ACID; VALPROIC ACID; POTASSIUM CHANNEL;

ANTICONVULSANT ACTIVITY; BIOENERGY; CITRIC ACID CYCLE; FATTY ACID OXIDATION; GLYCOLYSIS; HUMAN; KETOGENIC DIET; METABOLIC DISORDER; MITOCHONDRION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEIZURE; ANIMAL; LIPID DIET; METABOLISM; OXIDATIVE STRESS; PHYSIOLOGY; SEIZURES; TREATMENT OUTCOME;

ANIMALS; DIET, HIGH-FAT; HUMANS; KETOGENIC DIET; OXIDATIVE STRESS; POTASSIUM CHANNELS; SEIZURES; TREATMENT OUTCOME;

EID: 84938718749     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2015.07.034     Document Type: Review

References (69)

1. [1] Lennox, W.G., Cobb, S., Epilepsy from the standpoint of physiology and treatment. Medicine 7 (1928), 105–290.
2. [2] Peterman, M., The ketogenic diet in the treatment of epilepsy: a preliminary report. Am. J. Dis. Child. 28 (1924), 28–33.
3. [3] Huttenlocher, P.R., Wilbourn, A.J., Signore, J.M., Medium-chain triglycerides as a therapy for intractable childhood epilepsy. Neurology 21 (1971), 1097–1103.
4. [4] Neal, E.G., Chaffe, H., Schwartz, R.H., Lawson, M.S., Edwards, N., Fitzsimmons, G., Whitney, A., Cross, J.H., A randomized trial of classical and medium-chain triglyceride ketogenic diets in the treatment of childhood epilepsy. Epilepsia 50 (2009), 1109–1117.
5. [5] Neal, E.G., Chaffe, H., Schwartz, R.H., Lawson, M.S., Edwards, N., Fitzsimmons, G., Whitney, A., Cross, J.H., The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurol. 7 (2008), 500–506.
6. [6] Stafstrom, C.E., Rho, J.M., The ketogenic diet as a treatment paradigm for diverse neurological disorders. Front. Pharmacol., 3, 2012, 59.
7. [7] Freeman, J.M., Kossoff, E.H., Ketosis and the ketogenic diet, 2010: advances in treating epilepsy and other disorders. Adv. Pediatr. 57 (2010), 315–329.
8. [8] Morris, A.A., Cerebral ketone body metabolism. J. Inherit. Metab. Dis. 28 (2005), 109–121.
9. [9] Pierre, K., Pellerin, L., Monocarboxylate transporters in the central nervous system: distribution, regulation and function. J. Neurochem. 94:1 (2005), 1–14.
10. [10] Klein, P., Janousek, J., Barber, A., Weissberger, R., Ketogenic diet treatment in adults with refractory epilepsy. Epilepsy Behav. 19:4 (2010), 575–579.
11. [11] Mady, M.A., Kossoff, E.H., McGregor, A.L., Wheless, J.W., Pyzik, P.L., Freeman, J.M., The ketogenic diet: adolescents can do it, too. Epilepsia 44 (2003), 847–851.
12. [12] S.A. Masino, J.M. Rho, Mechanisms of Ketogenic Diet Action. In: J.L. Noebels, M., Avoli, M.A., Rogawski, R.W., Olsen, A.V. Delgado-Escueta (Eds.), Jasper's Basic Mechanisms of the Epilepsies, National Center for Biotechnology Information (US). Michael A. Rogawski, Antonio V. Delgado-Escueta, Jeffrey L. Noebels, Massimo Avoli. Richard W. Olsen., Bethesda (MD), 2012.
13. [13] Keith, H., Factors influencing experimentally produced convulsions. Arch. Neurol. Psychiatry 29 (1933), 148–154.
14. [14] Likhodii, S.S., Serbanescu, I., Cortez, M.A., Murphy, P., Snead, O.C., 3rd, Burnham, W.M., Anticonvulsant properties of acetone, a brain ketone elevated by the ketogenic diet. Ann. Neurol. 54 (2003), 219–226.
15. [15] Rho, J.M., Anderson, G.D., Donevan, S.D., White, H.S., Acetoacetate, acetone, and dibenzylamine (a contaminant in l-(+)-beta-hydroxybutyrate) exhibit direct anticonvulsant actions in vivo. Epilepsia 43 (2002), 358–361.
16. [16] Thio, L.L., Wong, M., Yamada, K.A., Ketone bodies do not directly alter excitatory or inhibitory hippocampal synaptic transmission. Neurology 54 (2000), 325–331.
17. [17] Yudkoff, M., Daikhin, Y., Nissim, I., Horyn, O., Lazarow, A., Luhovyy, B., Wehrli, S., Nissim, I., Response of brain amino acid metabolism to ketosis. Neurochem. Int. 47 (2005), 119–128.
18. [18] Dahlin, M., Elfving, A., Ungerstedt, U., Amark, P., The ketogenic diet influences the levels of excitatory and inhibitory amino acids in the CSF in children with refractory epilepsy. Epilepsy Res. 64 (2005), 115–125.
19. [19] Melo, T.M., Nehlig, A., Sonnewald, U., Neuronal-glial interactions in rats fed a ketogenic diet. Neurochem. Int. 48 (2006), 498–507.
20. [20] Bough, K.J., Wetherington, J., Hassel, B., Pare, J.F., Gawryluk, J.W., Greene, J.G., Shaw, R., Smith, Y., Geiger, J.D., Dingledine, R.J., Mitochondrial biogenesis in the anticonvulsant mechanism of the ketogenic diet. Ann. Neurol. 60 (2006), 223–235.
21. [21] Cheng, C.M., Hicks, K., Wang, J., Eagles, D.A., Bondy, C.A., Caloric restriction augments brain glutamic acid decarboxylase-65 and -67 expression. J. Neurosci. Res. 77 (2004), 270–276.
22. [22] Juge, N., Gray, J.A., Omote, H., Miyaji, T., Inoue, T., Hara, C., Uneyama, H., Edwards, R.H., Nicoll, R.A., Moriyama, Y., Metabolic control of vesicular glutamate transport and release. Neuron 68 (2010), 99–112.
23. [23] Ma, W., Berg, J., Yellen, G., Ketogenic diet metabolites reduce firing in central neurons by opening K(ATP) channels. J. Neurosci. 27 (2007), 3618–3625.
24. [24] Tanner, G.R., Lutas, A., Martinez-Francois, J.R., Yellen, G., Single K ATP channel opening in response to action potential firing in mouse dentate granule neurons. J. Neurosci. 31 (2011), 8689–8696.
25. [25] Won, Y.J., Lu, V.B., Puhl, H.L., Ikeda 3rd, S.R., Beta-hydroxybutyrate modulates N-type calcium channels in rat sympathetic neurons by acting as an agonist for the G-protein-coupled receptor FFA3. J. Neurosci. 33 (2013), 19314–19325.
26. [26] DeVivo, D.C., Leckie, M.P., Ferrendelli, J.S., McDougal, D.B. Jr., Chronic ketosis and cerebral metabolism. Ann. Neurol. 3 (1978), 331–337.
27. [27] Kim do, Y., Vallejo, J., Rho, J.M., Ketones prevent synaptic dysfunction induced by mitochondrial respiratory complex inhibitors. J. Neurochem. 114 (2010), 130–141.
28. [28] Masino, S.A., Kawamura, M. Jr., Ruskin, D.N., Geiger, J.D., Boison, D., Purines and neuronal excitability: links to the ketogenic diet. Epilepsy Res. 100 (2012), 229–238.
29. [29] Masino, S.A., Li, T., Theofilas, P., Sandau, U.S., Ruskin, D.N., Fredholm, B.B., Geiger, J.D., Aronica, E., Boison, D., A ketogenic diet suppresses seizures in mice through adenosine A(1) receptors. J. Clin. Invest. 121 (2011), 2679–2683.
30. [30] Rowley, S., Patel, M., Mitochondrial involvement and oxidative stress in temporal lobe epilepsy. Free Radic. Biol. Med. 62 (2013), 121–131.
31. [31] Suzuki, T., Motohashi, H., Yamamoto, M., Toward clinical application of the Keap1-Nrf2 pathway. Trends Pharmacol. Sci. 34 (2013), 340–346.
32. [32] Milder, J.B., Liang, L.P., Patel, M., Acute oxidative stress and systemic Nrf2 activation by the ketogenic diet. Neurobiol. Dis. 40 (2010), 238–244.
33. [33] Mazzuferi, M., Kumar, G., van Eyll, J., Danis, B., Foerch, P., Kaminski, R.M., Nrf2 defense pathway: experimental evidence for its protective role in epilepsy. Ann. Neurol. 74 (2013), 560–568.
34. [34] Maalouf, M., Rho, J.M., Oxidative impairment of hippocampal long-term potentiation involves activation of protein phosphatase 2A and is prevented by ketone bodies. J. Neurosci. Res. 86 (2008), 3322–3330.
35. [35] Maalouf, M., Sullivan, P.G., Davis, L., Kim, D.Y., Rho, J.M., Ketones inhibit mitochondrial production of reactive oxygen species production following glutamate excitotoxicity by increasing NADH oxidation. Neuroscience 145 (2007), 256–264.
36. [36] Kim do, Y., Davis, L.M., Sullivan, P.G., Maalouf, M., Simeone, T.A., van Brederode, J., Rho, J.M., Ketone bodies are protective against oxidative stress in neocortical neurons. J. Neurochem. 101 (2007), 1316–1326.
37. [37] Sullivan, P.G., Dube, C., Dorenbos, K., Steward, O., Baram, T.Z., Mitochondrial uncoupling protein-2 protects the immature brain from excitotoxic neuronal death. Ann. Neurol. 53 (2003), 711–717.
38. [38] Azzu, V., Brand, M.D., The on–off switches of the mitochondrial uncoupling proteins. Trends Biochem. Sci. 35 (2010), 298–307.
39. [39] Sullivan, P.G., Rippy, N.A., Dorenbos, K., Concepcion, R.C., Agarwal, A.K., Rho, J.M., The ketogenic diet increases mitochondrial uncoupling protein levels and activity. Ann. Neurol. 55 (2004), 576–580.
40. [40] Shimazu, T., Hirschey, M.D., Newman, J., He, W., Shirakawa, K., Le, N., Moan, C.A., Grueter, H., Lim, L.R., Saunders, R.D., Stevens, C.B., Newgard, R.V., de Cabo Farese, R. Jr., Ulrich, S., Akassoglou, K., Verdin, E., Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science 339 (2013), 211–214.
41. [41] Newman, J.C., Verdin, E., beta-hydroxybutyrate: much more than a metabolite. Diabetes Res. Clin. Pract. 106 (2014), 173–181.
42. [42] Youm, Y.H., Nguyen, K.Y., Grant, R.W., Goldberg, E.L., Bodogai, M., Kim, D., D'Agostino, D., Planavsky, N., Lupfer, C., Kanneganti, T.D., Kang, S., Horvath, T.L., Fahmy, T.M., Crawford, P.A., Biragyn, A., Alnemri, E., Dixit, V.D., The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat. Med. 21 (2015), 263–269.
43. [43] Kim do, Y., Hao, J., Liu, R., Turner, G., Shi, F.D., Rho, J.M., Inflammation-mediated memory dysfunction and effects of a ketogenic diet in a murine model of multiple sclerosis. PLoS One, 7, 2012, e35476.
44. [44] Vezzani, A., French, J., Bartfai, T., Baram, T.Z., The role of inflammation in epilepsy, nature reviews. Neurology 7 (2011), 31–40.
45. [45] Mantis, J.G., Centeno, N.A., Todorova, M.T., McGowan, R., Seyfried, T.N., Management of multifactorial idiopathic epilepsy in EL mice with caloric restriction and the ketogenic diet: role of glucose and ketone bodies. Nutr. Metab., 1, 2004, 11.
46. [46] Huttenlocher, P.R., Ketonemia and seizures: metabolic and anticonvulsant effects of two ketogenic diets in childhood epilepsy. Pediatr. Res. 10 (1976), 536–540.
47. [47] Stafstrom, C.E., Ockuly, J.C., Murphree, L., Valley, M.T., Roopra, A., Sutula, T.P., Anticonvulsant and antiepileptic actions of 2-deoxy-D-glucose in epilepsy models. Ann. Neurol. 65 (2009), 435–447.
48. [48] Garriga-Canut, M., Schoenike, B., Qazi, R., Bergendahl, K., Daley, T.J., Pfender, R.M., Morrison, J.F., Ockuly, J., Stafstrom, C., Sutula, T., Roopra, A., 2-Deoxy-D-glucose reduces epilepsy progression by NRSF-CtBP-dependent metabolic regulation of chromatin structure. Nat. Neurosci. 9 (2006), 1382–1387.
49. [49] Lian, X.Y., Khan, F.A., Stringer, J.L., Fructose-1,6-bisphosphate has anticonvulsant activity in models of acute seizures in adult rats. J. Neurosci. 27 (2007), 12007–12011.
50. [50] Fraser, D.D., Whiting, S., Andrew, R.D., Macdonald, E.A., Musa-Veloso, K., Cunnane, S.C., Elevated polyunsaturated fatty acids in blood serum obtained from children on the ketogenic diet. Neurology 60 (2003), 1026–1029.
51. [51] Michael-Titus, A.T., Priestley, J.V., Omega-3 fatty acids and traumatic neurological injury: from neuroprotection to neuroplasticity. Trends Neurosci. 37 (2014), 30–38.
52. [52] Schlanger, S., Shinitzky, M., Yam, D., Diet enriched with omega-3 fatty acids alleviates convulsion symptoms in epilepsy patients. Epilepsia 43 (2002), 103–104.
53. [53] Yuen, A.W., Sander, J.W., Fluegel, D., Patsalos, P.N., Bell, G.S., Johnson, T., Koepp, M.J., Omega-3 fatty acid supplementation in patients with chronic epilepsy: a randomized trial. Epilepsy Behav. 7 (2005), 253–258.
54. [54] Bromfield, E., Dworetzky, B., Hurwitz, S., Eluri, Z., Lane, L., Replansky, S., Mostofsky, D., A randomized trial of polyunsaturated fatty acids for refractory epilepsy. Epilepsy Behav. 12:1 (2008), 187–190.
55. [55] Taha, A.Y., Ryan, M.A., Cunnane, S.C., Despite transient ketosis, the classic high-fat ketogenic diet induces marked changes in fatty acid metabolism in rats. Metabolism 54 (2005), 1127–1132.
56. [56] Cullingford, T.E., Eagles, D.A., Sato, H., The ketogenic diet upregulates expression of the gene encoding the key ketogenic enzyme mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase in rat brain. Epilepsy Res. 49 (2002), 99–107.
57. [57] Taha, A.Y., Burnham, W.M., Auvin, S., Polyunsaturated fatty acids and epilepsy. Epilepsia 51 (2010), 1348–1358.
58. [58] Hadera, M.G., Smeland, O.B., McDonald, T.S., Tan, K.N., Sonnewald, U., Borges, K., Triheptanoin partially restores levels of tricarboxylic acid cycle intermediates in the mouse pilocarpine model of epilepsy. J. Neurochem. 129 (2014), 107–119.
59. [59] Willis, S., Stoll, J., Sweetman, L., Borges, K., Anticonvulsant effects of a triheptanoin diet in two mouse chronic seizure models. Neurobiol. Dis. 40 (2010), 565–572.
60. [60] Kovac, S., Abramov, A.Y., Walker, M.C., Energy depletion in seizures: anaplerosis as a strategy for future therapies. Neuropharmacology 69 (2013), 96–104.
61. [61] Haast, R.A., Kiliaan, A.J., Impact of fatty acids on brain circulation, structure and function. Prostaglandins Leukot. Essent. Fatty Acids 92 (2015), 3–14.
62. [62] Chang, P., Terbach, N., Plant, N., Chen, P.E., Walker, M.C., Williams, R.S., Seizure control by ketogenic diet-associated medium chain fatty acids. Neuropharmacology 69 (2013), 105–114.
63. [63] Chang, P., Orabi, B., Deranieh, R.M., Dham, M., Hoeller, O., Shimshoni, J.A., Yagen, B., Bialer, M., Greenberg, M.L., Walker, M.C., Williams, R.S., The antiepileptic drug valproic acid and other medium-chain fatty acids acutely reduce phosphoinositide levels independently of inositol in Dictyostelium. Dis. Models Mech. 5 (2012), 115–124.
64. [64] Chang, P., Zuckermann, A.M., Williams, S., Close, A.J., Cano-Jaimez, M., McEvoy, J.P., Spencer, J., Walker, M.C., Williams, R.S., Seizure control by derivatives of medium chain fatty acids associated with the ketogenic diet show novel branching-point structure for enhanced potency. J. Pharmacol. Exp. Ther. 352 (2015), 43–52.
65. [65] Walker, M.C., Williams, R.S., The search for better epilepsy treatments: from slime mould to coconuts. Biochem. Soc. Trans. 41 (2013), 1625–1628.
66. [66] Porta, N., Vallee, L., Lecointe, C., Bouchaert, E., Staels, B., Bordet, R., Auvin, S., Fenofibrate, a peroxisome proliferator-activated receptor-alpha agonist, exerts anticonvulsive properties. Epilepsia 50 (2009), 943–948.
67. [67] Rahman, M., Muhammad, S., Khan, M.A., Chen, H., Ridder, D.A., Muller-Fielitz, H., Pokorna, B., Vollbrandt, T., Stolting, I., Nadrowitz, R., Okun, J.G., Offermanns, S., Schwaninger, M., The beta-hydroxybutyrate receptor HCA2 activates a neuroprotective subset of macrophages. Nat. Commun., 5, 2014, 3944.
68. [68] Vezzani, A., Viviani, B., Neuromodulatory properties of inflammatory cytokines and their impact on neuronal excitability. Neuropharmacology, 96, 2014 Pt. A.
69. [69] Sada, N., Lee, S., Katsu, T., Otsuki, T., Inoue, T., Epilepsy treatment. Targeting LDH enzymes with a stiripentol analog to treat epilepsy. Science 347 (2015), 1362–1367.